Erythropoietin-based therapy represents the primary treatment and prevention option for anemia in chronic kidney disease. The drugs based on darbepoetin alfa are considered the most effective. However, so far, Russian patients had to use expensive drugs of foreign manufacturers. But, recently, BIOCAD announced the completion of clinical trials for the first Russian-made biosimilar of darbepoetin alfa (BCD-066), which was designed to treat anemia related to chronic kidney disease or cancer.
The investments in R&D amounted to 400 million rubles. The drug will be commercially available at the end of 2018 and, in 2021, the company plans to launch its own new innovative medicine for the treatment of anemia in patients with renal failure and cancer.
According to BIOCAD, the cost of biosimilar will be substantially lower than the cost of imported drugs, thus, improving access to required treatment and making it available to more patients.
According to the company estimations, in 2019, the sales of new drug will reach about 700 million rubles. At the first stage, it will be marketed only in Russia but, in the future, BIOCAD expects to export its biosimilar to the members of the Eurasian Customs Union. This, in turn, will help to increase sales of the drug to 3 billion rubles a year. BIOCAD expects to reach this figure in 5 years.